U.S. Markets open in 8 hrs 13 mins
  • S&P Futures

    3,673.25
    +8.75 (+0.24%)
     
  • Dow Futures

    30,001.00
    +69.00 (+0.23%)
     
  • Nasdaq Futures

    12,505.75
    +43.50 (+0.35%)
     
  • Russell 2000 Futures

    1,852.00
    +4.80 (+0.26%)
     
  • Crude Oil

    46.45
    +0.81 (+1.77%)
     
  • Gold

    1,843.20
    +2.10 (+0.11%)
     
  • Silver

    24.18
    +0.04 (+0.18%)
     
  • EUR/USD

    1.2155
    +0.0006 (+0.0486%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.28
    +0.11 (+0.52%)
     
  • GBP/USD

    1.3458
    +0.0006 (+0.0417%)
     
  • USD/JPY

    103.9080
    +0.0480 (+0.0462%)
     
  • BTC-USD

    19,264.72
    +7.14 (+0.04%)
     
  • CMC Crypto 200

    378.65
    +4.25 (+1.13%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,759.50
    -49.87 (-0.19%)
     

Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe

·4 min read

Innovation can help address screening backlog due to COVID-19 pandemic by streamlining breast imaging reading process

Hologic, Inc. (Nasdaq: HOLX) today announced the commercial availability in Europe of its 3DQuorum™ Imaging Technology, Powered by Genius AI™. The innovation was designed to help improve mammography efficiency and workflow, which is critical as clinics strive to manage the backlog of women whose routine breast screening was delayed due to the COVID-19 lockdown.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005023/en/

3DQuorum™ Imaging Technology, Powered by Genius AI™ (Graphic: Business Wire)

The 3DQuorum technology uses Genius AI-powered analytics to reconstruct high-resolution 3D data to produce 6mm "SmartSlices." These analytics identify clinically relevant regions of interest and preserve important features during reconstruction of the SmartSlices.1,2 SmartSlices expedite read time by reducing the number of images for radiologists to review, without compromising image quality, sensitivity or accuracy.1,2 With 3DQuorum technology, the number of 3D images to review is reduced by two-thirds, saving an average of one hour per eight hours of daily image interpretation time.1,2,3

"As we continue to operate in this new landscape, radiologists are facing the dual challenge of a serious backlog of women who need routine breast screening as well as a screening process that is lengthier due to COVID-19 protection measures," said Jan Verstreken, Hologic's Group President, International. "The more efficient workflow of 3DQuorum, is urgently necessary to help radiologists meet this challenge. This solution is a strong example of how Hologic continues to streamline workflow for radiologists by improving the reading experience without sacrificing accuracy or quality of work – a balance that our customers have come to expect."

In addition to the implications associated with the COVID-19 virus, radiologists are facing a growing need for improved workflow efficiency as digital breast tomosynthesis (DBT) becomes the gold standard for screening in Europe. Recently, the European Commission Initiative on Breast Cancer (EBIC) guidelines on breast cancer screening and diagnosis recommended for the first time the use of either DBT or digital mammography in screening. However, DBT creates an influx of large file sizes and images that can lengthen the image reading process for radiologists. This creates a need for solutions like 3DQuorum technology to help streamline workflow where possible.

More information on 3DQuorum technology can be found here and by visiting www.3dimensionsmammography.eu/3dquorum.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

3DQuorum™ Imaging Technology, Powered by Genius AI™, and Clarity HD™ high resolution imaging technology are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

SOURCE: Hologic, Inc.

1 Tech File: TFL-00059
2 Report: CSR-00116
3 Physician Labeling: MAN-06153

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005023/en/

Contacts

Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com

Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com